Smyd3-Shcbp1 expression could be reversed by trametinib treatment, and the combinatory treatment of trametinib with αPD1 enhances the function of effector T cells and sensitizes mammary tumors with elevated SMYD3 and SHCBP1 to αPD1 treatment. Here, SHCBP1 is linked to breast cancer.